Oliver Keil

Oliver Keil is an experienced professional in the field of drug delivery systems, currently serving as Chief Technology Officer at Pantherna Therapeutics GmbH since February 2018. Previously, Oliver held the position of Senior Consultant at LNP Consulting & Services and has extensive experience in lipid nanoparticle formulations, lipid and nucleic acid chemistry, and bioconjugation approaches. With a solid background in GMP and CMC, Oliver has been involved in IMPD writing and submissions to regulatory authorities. Prior roles include Head of CMC and Director of Lipid Chemistry/Formulation Technologies at Silence Therapeutics plc, as well as Senior Chemist/Formulation Developer at G.O.T. Therapeutics GmbH, contributing to the development of liposomal cytostatics and the synthesis of novel cationic lipids. Oliver earned a Ph.D. in Organic Chemistry from Bergische Universität Wuppertal and completed further studies at the University of Düsseldorf.